S
REGN icon

Sachetta’s Regeneron Pharmaceuticals REGN Stock Holding History

Sachetta’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26
Closed -$20.1K – 1174
2026
Q1 		$20.1K Hold
26
– – 0.01% 307
2025
Q4 		$20.1K Sell
26
-3
-10% -$2.04K 0.01% 292
2025
Q3 		$16.3K Buy
29
+13
+81% +$7.35K 0.01% 386
2025
Q2 		$8.4K Sell
16
-5
-24% -$2.79K ﹤0.01% 481
2025
Q1 		$13.3K Buy
21
+1
+5% +$688 0.01% 394
2024
Q4 		$14.2K Sell
20
-5
-20% -$4.2K 0.01% 397
2024
Q3 		$26.3K Buy
25
+1
+4% +$1.11K 0.01% 338
2024
Q2 		$25.9K Buy
24
+10
+71% +$9.69K 0.01% 310
2024
Q1 		$12.3K Hold
14
– – 0.01% 379
2023
Q4 		$12.3K Buy
+14
New +$11.5K 0.01% 379

Other funds holding REGN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
HCM
Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Sachetta's REGN Position: Q2 2026 in Review

Sachetta sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 26 shares — an estimated $20.1K sold.

Sachetta first reported a position in REGN in Q4 2023 and held it in 10 quarters. The position peaked at $26.3K in Q3 2024. 211 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Sachetta reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Sachetta sold 26 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $20.1K.
  • Sachetta first reported a position in Regeneron Pharmaceuticals in Q4 2023 and held it in 10 quarters.
  • Sachetta's Regeneron Pharmaceuticals position peaked at $26.3K in Q3 2024.
  • 211 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Sachetta's 13F filing for Q2 2026, filed 15 Jul 2026.